glp 1 arthritis Beyond weight loss: GLP-1 emerges as a disease-modifying signal in osteoarthritis Can Ozempic, Monjaro & GLP-1

Data Availability Statement The data is available from the corresponding author upon reasonable request.

Biology and clinical use of glucagon-like peptide-1 receptor agonists in vascular protection

[DOI] [PMC free article] [PubMed] [Google Scholar] 206.Ludvik B., Frias J.P., Tinahones F.J., Wainstein J., Jiang H., Robertson K.E

Categories of GLP-1 Drugs All GLP-1 drugs aim for similar outcomes but differ significantly in other respects

Given that obesity is a major modifiable risk factor for OSAS, and that the pathogenesis of OSAS involves metabolic dysregulation, systemic inflammation, and abnormal adipose tissue distribution, tirzepatide may offer multidimensional therapeutic benefits in this context (26)

XTALKS WEBINAR: Sarcopenia: Changes and Challenges in Body Composition with GLP-1 Receptor Agonist-based Weight Loss Therapies Live and On-Demand: Friday, September 6, 2024 , at 10am EDT (4pm CEST / EU-Central) Register for this free webinar to learn about the latest clinical trial data on GLP-1 receptor agonist-based therapies and their impact on weight loss and body composition